



Stock Symbol:	IMYN.OTC.BB
Price on 11/05/07:	\$4.75
Shares Outstanding:	272million
Market Capitalization:	\$1.29B
Estimated Shares in Public Float:	47,852,855

### **Executive Summary:**

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). (For more information on Immunosyn and SF-1019 go to [www.immunosyn.com](http://www.immunosyn.com))

### **SF-1019:**

Research suggests that the biopharmaceutical product SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). According to the International Diabetes Federation, globally, an approximated 246 million people have Diabetes Mellitus, of which 20-30 million have DN and 1 in 6 will develop a foot ulcer. The National MS Society estimates that worldwide 2.5 million people have MS.

The process has been initiated for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe.

### **Management:**

*Chairman of the Board: Douglas A. McClain, Jr.*

In 2002, McClain co-founded The Argyll Group, a boutique private equity investment banking and corporate finance firm. Now his focus is heading Argyll Biotechnologies, LLC, a subsidiary of The Argyll Group, in addition to his role with Immunosyn.

*CEO, President & Board Member: Stephen D. Ferrone*

Ferrone is a veteran marketing and sales executive with demonstrated national leadership of strategic and tactical initiatives. His extensive career includes nine years of service with ABN AMRO Asset Management and its Investment Funds Services Group as genesis architect of its marketing strategy. Recently, Ferrone provided strategic consulting services to the financial and biotech industries where he became associated with the principals of Argyll Biotechnologies, LLC.

*CFO: G. David Criner*

Criner has nearly 20 years of finance and accounting experience, including extensive operational experience in senior level finance positions with multiple public and privately held marketing and high tech companies.

### **Scientific Advisory Board:**

*Professor Angus Dalgleish, MBBS, BSc, MD, FRCP, RACP, FRCPATH, FMedSci*

Dalgleish is the Foundation Professor of Oncology at St. George's University of London. He is a co-discoverer of the CD4 receptor for HIV and has published many important papers on AIDS and HIV.

*Professor Kenneth Willeford, BSc, PhD*

Willeford is a Professor of Biochemistry and Molecular Biology at Mississippi State University. He is largely responsible for the discovery of SF-1019. Willeford has developed and published a large number of animal studies relating to the use of SF-1019, using various models, during the past seven years.

*Professor Jonathon Heeney, BSc, DVM (Honours), DVSc (Pathology), PhD, MRCVS*

Heeney is a Professor of Veterinary Science at Cambridge University, a member of the Eurovac Board and scientific board of the Cancer Vaccine Institute, and a former Professor at the Biomedical Primate Research Centre and head of the Department of Virology. Heeney has made a number of key contributions to AIDS vaccine development.

*David Maizels, MD, MSc, MRCS, LRCP*

Maizels has extensive knowledge of Caprine derived serum and is the lead clinician of the SF-1019 project. He has been a UK registered National Health Service (NHS) general medical practitioner since 1976 and has provided a wide range of general medical services within the NHS.

### **Investor Relations:**

*The Blaine Group*

[blaine@blainegroupinc.com](mailto:blaine@blainegroupinc.com) / 310-360-1499

The above contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.